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1. Introduction
   Sepsis is defined as the presence or presumed presence 
of an infection accompanied by evidence of a systemic 
response called the systemic inflammatory response 
syndrome[1]. Recently Vincent et al. defined as host’s 
deleterious, non-resolving inflammatory response to 
infection that leads to organ dysfunction[2]. Although 
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which authors have demonstrated that 
VL and VL-HIV co-infected patients 
which are affected by bacterial 
infections leading to sepsis, should 
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reduce nosocomial sepsis. Indwelling 
of central venous lines for immune-
suppressed patients such as VL 
and VL-HIV co-infected should be 
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sepsis can be caused by viruses and fungi, most is due 
to bacterial infections[3]. Recent review by Jawad et al. 
revealed that the incidence rate of sepsis ranged from 
56-91 cases per 100 000 people, with a reported mortality 
rate of 30%[4]. Incidence of sepsis is increasing due to 
nosocomial infection, aging of the population and the 
higher incidence of immunosuppressive conditions such 
as HIV/AIDS[5], visceral leishmaniasis (VL) and VL-HIV co-
infection and others[6-8]. 
   VL is one of the most neglected infectious diseases[9]. 
Over 90% of the estimated annual incidence in half a 
million VL cases worldwide occur in just six countries 
which are Bangladesh, India, Nepal, Sudan, Ethiopia 
and Brazil[10-12]. The highest prevalence of VL-HIV co-
infection in the world was reported from Eastern African 
region reached up to 40%[10,13].
   Patients with VL usually present with fever, weight loss, 
organomegaly and pancytopenia. Leishmania donovani, 
etiologic agent of VL, targets reticuloendothelial system, 
spleen, liver, bone marrow and lymph nodes[9]. Leishmania 
invade and replicate within host macrophages, evading 
innate and cell-mediated immune responses. Patients 
with VL show a continuum of immune responses from 
protective to non-protective[14]. Leucopenia, malnutrition 
and lack protective responses to Leishmania and other 
antigens including bacteria, predispose patients with VL to 
bacterial infections[15,16].
   Studies conducted on the prevalence of sepsis 
ranged from 3% to 28% among VL patients[6-8,17-21]. 
Although sepsis has high prevalence and affects the 
outcome of patients with VL, the causative agents and 
their antimicrobial susceptibility patterns are poorly 
understood. Under knowing the current magnitude of 
sepsis in immuno-compromised individuals such as VL 
and VL-HIV coinfected patients, it is important to take 
rational management for them. This review, therefore 
aims to compile available information on the prevalence, 
associated risk factors and etiologic agents of bacterial 
sepsis in patients with VL and VL-HIV co-infection.
2. Methods
   This review was developed after reviewing the pertinent 
information available about sepsis among patients with VL 
and VL-HIV co-infection from Hinari, Entrez-PubMed and 
Google Scholar web sites. 
3. Sepsis
3.1. Prevalence of sepsis 
   The prevalence of sepsis in patients with VL and VL-
HIV coinfected patients in the world is not clearly known. 
Recent studies showed sepsis was a main factor that 
affected the treatment outcome of patients with VL[22]. 
Bacterial infections and sepsis among VL and VL-HIV 
coinfected patients have been reported ranging from 15% 
to 84% and 3% to 28%, respectively (Table 1).
Table 1
Prevalence of bacterial infections and sepsis among patients with VL.
Country of 
study 
Bacterial 
infections
Sepsis Study group Reference
Brazil 52.4% NR Admitted VL (n=63) [24]
Brazil 60.0%  4.2% Admitted VL (n=30)   [6]
Brazil 27.5%  9.1% Paediatric VL (n=120) [21]
Iran 41.0% 13.0% Paediatric VL (n=54)   [7]
Albania 60.0% NR VL patients (n=50) [25]
Albania 84.0%  3.0% Admitted VL (n=1 210) [20]
Iran 42.0% 28.0% Paediatric VL (n=60) [17]
Ethiopia 42.8%  5.0% Non-HIV VL (n=247)   [8]
Ethiopia 23.1% NR Pediatric VL (n=77) [26]
Ethiopia 15.0%  7.0% All VL (n=81) [18]
Ethiopia   16.0%+  10.0%+ Adult VL (n=241) [19]
    40.0%++    14.0%++
NR: Not reported, +: HIV negative, ++: HIV positive.
3.2. Associated risk factors
   The increased susceptibility of VL patients to bacterial 
infections leads sepsis to be multi-factorial. Immuno-
suppression, leucopenia and malnutrition are the most 
important factors associated with susceptibility to bacterial 
infections[8,17]. Extreme age (age <1 year old and >40 years 
old) and HIV are the factors associated with bacterial 
sepsis[8]. Malnutrition, pulmonary rales, severe anemia, 
severe absolute neutropenia and higher neutrophil count 
were also identified as risk factors related to bacterial 
infections that lead to death in patients with VL[15]. 
Neutropenia associated with bacteremia is common in 
immune-compromised patients including cancer patients[23]. 
   Increased exposure to potentially resistant bacteria in 
nursing homes and utilization of insufficiently sterilized 
medical devices including indwelling catheters and central 
venous lines will also increase risks. Patients with VL treated 
in hospital had significantly higher rates of complications 
than those treated on outpatient basis (P<0.001)[8].
Mengistu Endris et al./Asian Pac J Trop Biomed 2014; 4(11): 871-875 873
3.3. Sources for sepsis
   The sources for sepsis are bacterial infections elsewhere 
in the body that include: lungs, wounds, soft tissues, 
central nervous system and urinary tract infections. 
Bacterial infections (such as pneumonia, otitis media, and 
gastrointestinal infections) cause sepsis, which are common 
in patients with VL ranging from 15% to 84%[6-8,17-21,24-26]. 
Patients with VL will stay in hospital for at least 30 d for the 
treatment of VL. In this period, they will be treated with 
the drugs (such as sodium stibogluconate, amphotericin 
b) intravenously. This intravenous dwelling may also 
contribute to the entrance of bacterial agents. A few studies 
in Ethiopia also reported bacterial infections ranging from 
15% to 42.8% and 40% in patients with VL and VL-HIV co-
infection, respectively[8,18,19,26].
3.4. Etiologic agents and their antimicrobial susceptibility 
patterns
   Both Gram-positive and Gram-negative bacteria were 
isolated from patients with VL (Table 2). Among the Gram-
positives, Staphylococcus aureus were the predominateing 
isolate. Unexpected Gram-negative bacteria such as 
Shigella was also reported from a VL case in Ethiopia[27]. 
Although some bacteria were isolated from patients with 
VL, their antimicrobial susceptibility patterns are not well 
studied (Table 2). 
3.5. Mortality due to sepsis
   Sepsis is a life-threatening disease that may lead to 
shock, multiple organ failure, and death, especially if 
not recognized early and treated promptly. Millions of 
people die of sepsis every year worldwide[28]. Bloodstream 
infections are usually serious infections typically causing a 
prolonged hospital stay, increased cost and risk of mortality, 
especially when it occurs with other co-infections like 
HIV[29]. Sepsis is the primary cause of death that contributes 
34% to 75% of the total deaths in patients with VL[18,20-22,26]. 
Bacterial sepsis still remains the primary cause of death 
from infection in spite of advanced modern medicine, 
including vaccines, antibiotics and acute care.
   Sepsis was one of the associated factors with poor 
treatment outcome (death) in patients with VL and VL- HIV 
coinfected. Patients with VL and sepsis have six times [odds 
ratio (OR)=6.44] more risk to die than with VL but not sepsis. 
In patients with VL-HIV coinfection and sepsis, this risk 
raises to nine times (OR=9.06)[19].
4. Conclusion 
   Sepsis is an important health problem causing death of 
VL and VL-HIV coinfected patients. Sepsis in VL patients is 
associated with immune suppression, pancytopenia, HIV 
coinfection, age <1 year old and >40 years old, indwelling of 
central venous lines and hospitalization. Bacterial infections 
such as pneumonia, otitis media, and gastrointestinal 
infections leading to sepsis were common among VL 
patients. Both Gram-positive and Gram-negative bacteria 
were isolated from blood cultures of sepsis suspected VL 
patients. VL and VL-HIV coinfected patients that are affected 
by bacterial infections (such as pneumonia, otitis media, 
gastrointestinal infections), which cause sepsis, should 
be diagnosed and treated early. Optimal infection control 
measures should be taken by concerned bodies in order 
to reduce nosocomial sepsis. Indwelling of central venous 
Table 2
Bacterial agents isolated from blood culture of patients with VL and HIV co-infection.
Gram-reaction Bacteria isolated Case/total (%) Susceptibility testing Country References
Gram-positives
Staphylococcus aureus 
  3/54 (5.6%) DNR Iran  [7]
3/247 (1.2%) ND Ethiopia  [8]
Streptococcus pneumonia 1* ND Spain [30]
Gram-negatives
Acinetobacter baumannii 1* MDR Greece [31]
Enterobacter species
  1/24 (4.2%) ND Brazil  [6]
  1/54 (1.9%) DNR Iran  [7]
Escherichia coli 
1
*
ND Spain [30]
1/247 (0.4%) ND Ethiopia  [8]
Klebsiella pneumonia   2/54 (3.7%) DNR Iran  [7]
Pseudomonas aeroginasa 
  1/54 (1.9%) DNR Iran  [7]
1/247 (0.4%) ND Ethiopia  [8]
Shigella species 1* D Ethiopia [27]
*: Case report, ND: not done, DNR: done but not reported, MDR: multiple drug resistant, D: done (sensitive to all tested except ampicillin).
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lines for immunosuppressed patients such as VL and VL-
HIV coinfection should be reduced as much as possible. 
It is necessary to further study about sepsis causative 
agents, their antibiotic pattern and associated factor 
among VL and VL-HIV coinfected patients.
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Comments 
Background
   Sepsis is the presence of an infection accompanied by 
evidence of systemic inflammatory response syndrome. 
Incidence of sepsis is increasing due to nosocomial 
infection, aging of the population and the higher incidence 
of immunosuppressive conditions such as HIV/AIDS, VL and 
VL-HIV co-infection and others. VL is one of the neglected 
diseases in the world, affecting the poorest segment of 
rural populations. Studies have shown that the prevalence 
of sepsis ranged from 3% to 28% among VL patients. 
Therefore, knowing the current magnitude of sepsis in 
immuno-compromised individuals such as VL and VL-HIV 
co-infected patients is important for rational management 
of patients.   
Research frontiers
   A s  V L  a n d  V L - H I V  c o - i n f e c t e d  p a t i e n t s  a r e 
immunocompromized patients and studies showed that 
bacterial sepsis is becoming an important concern in this 
population segment. VL is one of the neglected diseases 
in developing countries where bacterial infection is 
equally important, hence addressing this problem may be 
important for increasing awareness of the community and 
give better attention for patient management.
Related reports
   In recent reports sepsis was the main factor that affects 
the treatment outcome of patients with VL (Hussein et 
al., 2001). Bacterial infections and sepsis among VL and 
VL-HIV co-infected patients have been reported ranging 
from 15% (Tadesse and Hurissa, 2009) to 84% (Petrela et al., 
2010) and 3% (Petrela et al., 2010) to 28% (Barati et al., 2008) 
respectively. Sepsis is the primary cause of death that 
contributes 34% to 75% of the total deaths in patients with 
VL (Rocha et al., 2011). 
Innovations and breakthroughs
   A s  V L  and  V L - H I V  co- in f ec t ed  pa t i en t s  a r e 
immunocompromized patients, in the present study 
authors have demonstrated the importance of bacterial 
sepsis in this population segments which become 
important public health concern. 
Applications
   It has been found that sepsis is the primary cause of 
death that contributes to a significant number of deaths in 
patients with VL. Addressing this issue may be important 
for increasing awareness of the community and give better 
attention for patient management.
Peer review
   This review is a valuable work in which authors have 
demonstrated that VL and VL-HIV co-infected patients 
affected by bacterial infections leading to sepsis, should 
be diagnosed and treated early. Optimal infection control 
measures should be timely taken in order to reduce 
nosocomial sepsis. Indwelling of central venous lines for 
immune-suppressed patients such as VL and VL-HIV co-
infected should be reduced as much as possible. 
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